Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aquestive Therapeutics Inc

Current price
2.39 USD +0.04 USD (+1.70%)
Last closed 2.25 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 141 546 672 USD
Yield for 12 month +151.24 %
21.11.2021 - 28.11.2021

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Address: 30 Technology Drive, Warren, NJ, United States, 07059


WallStreet Target Price

6.33 USD

P/E ratio

Dividend Yield

Current Year

+47 680 000 USD

Last Year

+50 832 000 USD

Current Quarter

+13 002 000 USD

Last Quarter

+13 241 000 USD

Current Year

+28 294 000 USD

Last Year

+35 843 000 USD

Current Quarter

+8 204 000 USD

Last Quarter

+6 624 000 USD

Key Figures AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -20 462 000 USD
Operating Margin TTM -18.28 %
PE Ratio
Return On Assets TTM -24.6 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 6.33 USD
Revenue TTM 48 059 000 USD
Book Value -1.54 USD
Revenue Per Share TTM 0.83 USD
Dividend Share
Quarterly Revenue Growth YOY 13.4 %
Dividend Yield
Gross Profit TTM 28 294 000 USD
Earnings Share -0.22 USD
Diluted Eps TTM -0.22 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -25.2 %

Dividend Analytics AQST

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.7944
Price Sales TTM 1.0139
Enterprise Value EBITDA -1.5989
Price Book MRQ

Financials AQST

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AQST

For 52 weeks

0.72 USD 2.69 USD
50 Day MA 1.57 USD
Shares Short Prior Month 1 985 439
200 Day MA 1.56 USD
Short Ratio 10.4
Shares Short 1 954 375
Short Percent 3.78 %